摘要
目的探讨CRABPII和E-FABP在乳腺浸润性导管癌中的表达差异及与临床病理特征和预后的关系。方法采用免疫组化SP法检测152例乳腺浸润性导管癌中CRABPII和E-FABP的表达。结果 CRABPII和EFABP在乳腺浸润性导管癌中的表达存在差异(P<0.05),E-FABP 72.4%的阳性率高于CRABPII的33.6%。CRABPII和E-FABP的差异性表达与肿瘤有/无转移、TNM分期有关(P<0.05),与患者预后无关(P>0.05)。结论在乳腺浸润性导管癌中,E-FABP在肿瘤中的阳性表达率较CRABPII高,伴有癌转移、TNM分期晚的肿瘤阳性率更高。调节肿瘤细胞中CRABPII/E-FABP的比例有望成为乳腺癌个性化靶向治疗研究的新方向。
Objective To study the differential expression between CRABPII and E-FABP in breast invasion ductal carcinoma （IDC）and their clinical significance. Methods CRABPII and E-FABP proteins were detected in 152 cases of IDC by SP method of immunohistochemical staining. Results CRABPII and E-FABP showed different expression distribution in IDC （P 〈 O. 05 ）. The expression level of E-FABP had a recognizable advantage over that of CRABPII. The differential expression between CRABPII and E-FABP was correlated to the metastasis and TNM staging, but not correlated to the prognosis of IDC patients （P 〉 0. 05 ）. Conclusions The expression level of E-FABP has a recognizable advantage over that of CRABPII in IDC, the later the TNM staging is, along with cancer metastasis, the more likely the expression of E-FABP would dominate. Regulating the CRABPII/E-FABP ratio in tumor cells may be the new direction of research on target therapy of breast carcinoma.
出处
《诊断病理学杂志》
CSCD
北大核心
2013年第10期638-641,共4页
Chinese Journal of Diagnostic Pathology
基金
四川省卫生厅科研资助课题(100174)
